Alzheimer’s
Alzheimer’s research ‘turning point’
October 11, 2013Research and Development, Sales and Marketing Alzheimer's, Alzheimer’s, MRC, research
There is new hope that Alzheimer’s disease could be cured, according to a discovery by scientists from the Medical Research …
Lundbeck/Otsuka Alzheimer’s drug improves cognition
July 17, 2013Research and Development, Sales and Marketing Alzheimer's, Lundbeck, Otsuka
Lundbeck and partner Otsuka have posted positive Phase II results for their experimental Alzheimer’s drug. The latest data show statistically …
Dementia rates declining in UK
July 17, 2013Research and Development, Sales and Marketing Alzheimer's, UK, brain, dementia
A new study has found that the rate of dementia in Britain has decreased over the past two decades, contrary …
Lilly revisits Alzheimer’s drug
July 15, 2013Research and Development, Sales and Marketing Alzheimer's, lilly, solanezumab
Eli Lilly & Co is to run yet another trial of its Alzheimer’s drug solanezumab, which failed twice in Phase …
Lilly increases Alzheimer’s R&D
April 18, 2013Research and Development, Sales and Marketing Alzheimer's, lilly
Eli Lilly and Company has bought a new diagnostic technology which may help point to a different way of treating …
Merck makes Alzheimer’s deal
March 14, 2013Research and Development, Sales and Marketing Alzheimer's, Merck
Merck is teaming up with Texas-based Luminex Corporation to develop a companion diagnostic to help in its dementia programme. The …
FDA offers Alzheimer’s guidance
February 11, 2013Research and Development, Sales and Marketing Alzheimer's, FDA, Roche, lilly
The FDA has issued guidance to help companies developing new treatments for patients with early-stage Alzheimer’s disease. The US regulator’s …
Alzheimer’s drug lowers mortality
December 7, 2012Sales and Marketing Alzheimer's, Janssen, Razadyne, Roche, lilly
A study of Janssen Pharmaceuticals’ Razadyne suggests that the Alzheimer’s drug helped patients stay alive longer and slowed their cognitive …
New drugs for Alzheimer’s trial
October 15, 2012Research and Development, Sales and Marketing Alzheimer's, Roche, lilly
Roche and Eli Lilly are providing drugs free of charge to US investigators conducting a worldwide trial of Alzheimer’s disease …
Lilly’s Alzheimer’s drug fails in phase III
August 24, 2012Sales and Marketing Alzheimer's, EXPEDITION, lilly, solanezumab
Lilly has announced that its Alzheimer’s drug candidate solanezumab has failed its primary endpoints in two key phase III trials. …
Pfizer/Janssen Alzheimer’s drug dropped after failure
August 7, 2012Research and Development, Sales and Marketing Alzheimer's, Janssen, Pfizer, bapineuzumab
Pfizer and Janssen have decided to drop their investigational Alzheimer’s drug bapineuzumab after it failed a second late-stage study. The …
Pfizer and Janssen’s Alzheimer’s drug fails
July 24, 2012Research and Development, Sales and Marketing Alzheimer's, Janssen, Pfizer, bapineuzumab
Pfizer and Janssen’s investigational Alzheimer’s drug bapineuzumab is no better than placebo, according to a new study. The Phase III …
AZ sets up Alzheimer’s research collaborative
July 13, 2012Research and Development Alzheimer's, AstraZeneca, neuroscience
AstraZeneca and Dr Steven Paul of Weill Cornell Medical College have unveiled a new research alliance that brings four leading …
AstraZeneca buys neuroscience molecules
July 13, 2012Research and Development Alzheimer's, AstraZeneca, neuroscience
AstraZeneca is to acquire a portfolio of neuroscience assets from Link Medicine, a private US pharma firm.The deal is the …
MPs warn of dementia delays
July 3, 2012Research and Development, Sales and Marketing APPG, Alzheimer's, dementia, government
Patients with dementia are facing huge delays in their diagnosis and treatment according to a group of MPs and peers. …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
